ALLIANCEBERNSTEIN HOLDING L.P. (AB)
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
📈 **POSITIVE** • High confidence analysis (80%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical